Stockreport

Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF - Successful nomination of lead SAFEbody candidates triggers milestone payment - SAN DIEGO and SUZHOU, China, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene [Read more]